Lee Seungbok, Park Ha Young, Kang So Young, Kim Seok Jin, Hwang Jinha, Lee Seungho, Kwak Soo Heon, Park Kyong Soo, Yoo Hae Yong, Kim Won Seog, Kim Jong-Il, Ko Young Hyeh
Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Korea.
Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.
Oncotarget. 2015 Jul 10;6(19):17764-76. doi: 10.18632/oncotarget.3776.
Extranodal NK/T-cell lymphoma nasal type (ENKL) is a rare type of non-Hodgkin lymphoma that more frequently occurs in East Asia and Latin America. Even though its molecular background has been discussed in the last few years, the current knowledge does not explain the disease pathogenesis in most cases of ENKL. Here, we performed multiple types of next-generation sequencing on 34 ENKL samples, including whole-exome sequencing (9 cancer tissues and 4 cancer cell lines), targeted sequencing (21 cancer tissues), and RNA sequencing (3 cancer tissues and 4 cancer cell lines). Mutations were found most frequently in 3 genes, STAT3, BCOR, and MLL2 (which were present in 9, 7, and 6 cancer samples, respectively), whereas there were only 2 cases of JAK3 mutation. In total, JAK/STAT pathway- and histone modification-related genes accounted for 55.9% and 38.2% of cancer samples, respectively, and their involvement in ENKL pathogenesis was also supported by gene expression analysis. In addition, we provided 177 genes upregulated only in cancer tissues, which appear to be linked with angiocentric and angiodestructive growth of ENKL. In this study, we propose several novel driver genes of ENKL, and show that these genes and their functional groups may be future therapeutic targets of this disease.
鼻型结外NK/T细胞淋巴瘤(ENKL)是一种罕见的非霍奇金淋巴瘤,在东亚和拉丁美洲更为常见。尽管在过去几年中已经讨论了其分子背景,但目前的知识并不能解释大多数ENKL病例的疾病发病机制。在此,我们对34例ENKL样本进行了多种类型的二代测序,包括全外显子测序(9个癌组织和4个癌细胞系)、靶向测序(21个癌组织)和RNA测序(3个癌组织和4个癌细胞系)。在3个基因中最常发现突变,即STAT3、BCOR和MLL2(分别存在于9个、7个和6个癌症样本中),而JAK3突变仅有2例。总的来说,JAK/STAT通路相关基因和组蛋白修饰相关基因分别占癌症样本的55.9%和38.2%,基因表达分析也支持它们参与ENKL发病机制。此外,我们提供了177个仅在癌组织中上调的基因,这些基因似乎与ENKL的血管中心性和血管破坏性生长有关。在本研究中,我们提出了几个ENKL的新型驱动基因,并表明这些基因及其功能组可能是该疾病未来的治疗靶点。